PD-1-IN-17 (TFA)

PD-1-IN-17 (TFA)

• UNSPSC Description: PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1].
• Target Antigen: PD-1/PD-L1
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/pd-1-in-17-tfa.html
• Solubility: 10 mM in DMSO
• Smiles: OC[C@@H](C(O)=O)NC(N[C@H](C1=NN=C([C@@H](N)[C@H](O)C)O1)CCC(N)=O)=O.OC(C(F)(F)F)=O
• Molecular Weight: 488.37
• References & Citations: [1]Pottayil Govindan Nair Sasikumar, et al. 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators. WO2015033301A1.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported